Levaquin Linked to Peripheral Neuropathy

Posted On June 10th, 2015 By CSSFIRM.COM

Levaquin, an antibiotic manufactured Ortho-McNeil-Janssen Pharmaceuticals, a Johnson & Johnson company, has been linked to a rare form of nerve damage called peripheral neuropathy. Johnson & Johnson currently faces thousands of product liability lawsuits filed by people who allegedly developed peripheral neuropathy and irreversible nerve damage after taking Levaquin.

What is Levaquin?

Levaquin, approved by the FDA in 1996, is a member of the fluoroquinolone class of antibiotics prescribed to treat bacterial infections of the lungs, urinary tract, and skin. Despite the availability of loss costly and safer antibiotics, Johnson & Johnson and Ortho-McNeil launched strong marketing efforts to convince physicians that the drug offers patients advantages over less-costly alternatives, but because of Levaquin’s many serious side effects, fewer people now believe that its benefits outweigh the risks.

Levaquin Injuries

Levaquin and other antibiotics in the fluoroquinolone class have recently been linked to peripheral neuropathy, a disorder that occurs when nerves between the brain and body become damaged and are unable to effectively communicate with each other. There are over 100 separate and distinct forms of peripheral neuropathy, depending on which nerves have been damaged. Symptoms of neuropathy may include:

  • Pain
  • Burning and tingling
  • Numbness
  • Weakness
  • Change in sensation to light touch, pain, or temperature
  • Change in sense of body position
  • Loss of reflexes
  • Paresthesia
  • Muscle wasting
  • Paralysis

Levaquin Complaints

In August 2013, the FDA issued a Drug Safety Communication stating that patients treated with fluoroquinolone antibiotics, including Levaquin, had been diagnosed with peripheral neuropathy. Johnson & Johnson is currently facing thousands of product liability lawsuits filed by those who allegedly developed peripheral neuropathy as a result of taking Levaquin. The complaints allege that the drug maker did not provide adequate warnings about Levaquin’s potential to cause these conditions. According to the FDA, over 60 percent of fluoroquinolone-induced tendon injuries were related to Levaquin use.

Share us on